Our latest articles

Vantage logo

Zantac burns big pharma

As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.